nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

17.06.2023 | Original Article

[¹⁸F] AlF-NOTA-FAPI-04 PET/CT can predict treatment response and survival in patients receiving chemotherapy for inoperable pancreatic ductal adenocarcinoma

verfasst von: Ziyuan Zhu, Kai Cheng, Zhang Yun, Xiang Zhang, Xiaoyu Hu, Jing Liu, Fuhao Wang, Zheng Fu, Jinbo Yue

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 11/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We investigated whether uptake of [¹⁸F] AlF-NOTA-FAPI-04 on positron emission tomography/computed tomography (PET/CT) could predict treatment response and survival in patients with pancreatic ductal adenocarcinoma (PDAC).

Methods

We prospectively evaluated 47 patients with histopathologically confirmed primary PDAC who provided pretreatment [¹⁸F] AlF-NOTA-FAPI-04 scans to detect fibroblast activation protein (FAP) on the tumor surface by uptake of [¹⁸F] AlF-NOTA-FAPI-04. PDAC specimens were immunohistochemically stained with cancer-associated fibroblast (CAF) markers. We obtained a second PET scan after one cycle of chemotherapy to study changes in FAPI uptake variables from before to during treatment. Correlations between baseline PET variables and CAF-related immunohistochemical markers were assessed with Spearman’s rank test. Cox regression and Kaplan–Meier methods were used to assess relationships between disease progression and potential predictors. Receiver operating characteristic (ROC) curve analysis was used to define the optimal cut-off points for distinguishing patients according to good response vs. poor response per RECIST v.1.1.

Results

The FAPI PET variables maximum and mean standardized uptake values (SUV_max, SUV_mean), metabolic tumor volume (MTV), and total lesion FAP expression (TLF) were positively correlated with CAF markers (FAP, α-smooth muscle actin, vimentin, S100A4, and platelet-derived growth factor receptor α/β, all P < 0.05). MTV was associated with survival in patients with inoperable PDAC (all P < 0.05). Cox multivariate regression showed that MTV was associated with overall survival (MTV hazard ratio [HR] = 1.016, P = 0.016). Greater changes from before to during chemotherapy in SUV_max, MTV, and TLF were associated with good treatment response (all P < 0.05). ΔMTV, ΔTLF, and ΔSUV_max had larger areas under the curve than ΔCA19-9 for predicting treatment response. Kaplan–Meier analysis showed that the extent of change in MTV and TLF from before to after treatment predicted progression-free survival, with cut-off values (based on medians) of − 4.95 for ΔMTV (HR = 8.09, P = 0.013) and − 77.83 for ΔTLF (HR = 4.62, P = 0.012).

Conclusions

A higher baseline MTV on [¹⁸F] AlF-NOTA-FAPI-04 scans was associated with poorer survival in patients with inoperable PDAC. ΔMTV was more sensitive for predicting response than ΔCA19-9. These results are clinically meaningful for identifying patients with PDAC who are at high risk of disease progression.

Nur mit Berechtigung zugänglich

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics. CA: Cancer J Clin. 2023;73:17–48. https://doi.org/10.3322/caac.21763.CrossRefPubMed

Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open. 2021;4:e214708. https://doi.org/10.1001/jamanetworkopen.2021.4708.CrossRefPubMedPubMedCentral

Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005;93:195–9. https://doi.org/10.1038/sj.bjc.6602687.CrossRefPubMedPubMedCentral

Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, et al. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol. 2012;23:1713–22. https://doi.org/10.1093/annonc/mdr561.CrossRefPubMedPubMedCentral

Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer. 2005;93:740–3. https://doi.org/10.1038/sj.bjc.6602760.CrossRefPubMedPubMedCentral

Kondo N, Murakami Y, Uemura K, Hayashidani Y, Sudo T, Hashimoto Y, et al. Prognostic impact of perioperative serum CA 19–9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol. 2010;17:2321–9. https://doi.org/10.1245/s10434-010-1033-0.CrossRefPubMed

Dumitra S, Jamal MH, Aboukhalil J, Doi SA, Chaudhury P, Hassanain M, et al. Pancreatic cancer and predictors of survival: comparing the CA 19–9/bilirubin ratio with the McGill Brisbane Symptom Score. HPB. 2013;15:1002–9. https://doi.org/10.1111/hpb.12085.CrossRefPubMedPubMedCentral

La Greca G, Sofia M, Lombardo R, Latteri S, Ricotta A, Puleo S, et al. Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein. World J Gastroenterol. 2012;18:4150–5. https://doi.org/10.3748/wjg.v18.i31.4150.CrossRefPubMedPubMedCentral

Zhang L, Sanagapalli S, Stoita A. Challenges in diagnosis of pancreatic cancer. World J Gastroenterol. 2018;24:2047–60. https://doi.org/10.3748/wjg.v24.i19.2047.CrossRefPubMedPubMedCentral

10.

Strobel O, Büchler MW. Pancreatic cancer: FDG-PET is not useful in early pancreatic cancer diagnosis. Nat Rev Gastroenterol Hepatol. 2013;10:203–5. https://doi.org/10.1038/nrgastro.2013.42.CrossRefPubMed

11.

Jha P, Bijan B. PET/CT for pancreatic malignancy: potential and pitfalls. J Nucl Med Technol. 2015;43:92–7. https://doi.org/10.2967/jnmt.114.145458.CrossRefPubMed

12.

Koustoulidou S, Hoorens MWH, Dalm SU, Mahajan S, Debets R, Seimbille Y, et al. Cancer-associated fibroblasts as players in cancer development and progression and their role in targeted radionuclide imaging and therapy. Cancers. 2021;13. https://doi.org/10.3390/cancers13051100.

13.

de Sostoa J, Fajardo CA, Moreno R, Ramos MD, Farrera-Sal M, Alemany R. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager. J Immunother Cancer. 2019;7:19. https://doi.org/10.1186/s40425-019-0505-4.CrossRefPubMedPubMedCentral

14.

Christiansen VJ, Jackson KW, Lee KN, Downs TD, McKee PA. Targeting inhibition of fibroblast activation protein-α and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments. Neoplasia (New York, NY). 2013;15:348–58. https://doi.org/10.1593/neo.121850.CrossRef

15.

Li Z, Sun C, Qin Z. Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming. Theranostics. 2021;11:8322–36. https://doi.org/10.7150/thno.62378.CrossRefPubMedPubMedCentral

16.

Šimková A, Bušek P, Šedo A, Konvalinka J. Molecular recognition of fibroblast activation protein for diagnostic and therapeutic applications. Biochimica et Biophysica Acta Proteins and Proteomics. 2020;1868:140409. https://doi.org/10.1016/j.bbapap.2020.140409.CrossRefPubMed

17.

Mazur A, Holthoff E, Vadali S, Kelly T, Post SR. Cleavage of type I collagen by fibroblast activation protein-α enhances class A scavenger receptor mediated macrophage adhesion. PloS one. 2016;11:e0150287. https://doi.org/10.1371/journal.pone.0150287.CrossRefPubMedPubMedCentral

18.

Puré E, Blomberg R. Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics. Oncogene. 2018;37:4343–57. https://doi.org/10.1038/s41388-018-0275-3.CrossRefPubMedPubMedCentral

19.

Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020;17:487–505. https://doi.org/10.1038/s41575-020-0300-1.CrossRefPubMedPubMedCentral

20.

Liermann J, Syed M, Ben-Josef E, Schubert K, Schlampp I, Sprengel SD, et al. Impact of FAPI-PET/CT on target volume definition in radiation therapy of locally recurrent pancreatic cancer. Cancers. 2021;13. https://doi.org/10.3390/cancers13040796.

21.

Wei Y, Cheng K, Fu Z, Zheng J, Mu Z, Zhao C, et al. [(18)F]AlF-NOTA-FAPI-04 PET/CT uptake in metastatic lesions on PET/CT imaging might distinguish different pathological types of lung cancer. Eur J Nucl Med Mol Imaging. 2022;49:1671–81. https://doi.org/10.1007/s00259-021-05638-z.CrossRefPubMed

22.

Thuillier P, Maajem M, Schick U, Blanc-Beguin F, Hennebicq S, Metges JP, et al. Clinical Assessment of 177Lu-DOTATATE quantification by comparison of SUV-based parameters measured on both post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in patients with neuroendocrine tumors: a feasibility study. Clin Nucl Med. 2021;46:111–8. https://doi.org/10.1097/rlu.0000000000003412.CrossRefPubMed

23.

Hu X, Zhou T, Ren J, Duan J, Wu H, Liu X, et al. Response prediction using (18)F-FAPI-04 PET/CT in patients with esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy. J Nucl Med. 2022. https://doi.org/10.2967/jnumed.122.264638.

24.

Ren B, Cui M, Yang G, Wang H, Feng M, You L, et al. Tumor microenvironment participates in metastasis of pancreatic cancer. Mol Cancer. 2018;17:108. https://doi.org/10.1186/s12943-018-0858-1.CrossRefPubMedPubMedCentral

25.

Melucci AD, Chacon AC, Burchard PR, Tsagkalidis V, Casabianca AS, Goyal S, et al. The impact of carbohydrate antigen 19–9 on survival in patients with clinical stage I and II pancreatic cancer. Ann Surg Oncol. 2022;29:8536–47. https://doi.org/10.1245/s10434-022-12497-x.CrossRefPubMedPubMedCentral

26.

Halm U, Schumann T, Schiefke I, Witzigmann H, Mössner J, Keim V. Decrease of CA 19–9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer. 2000;82:1013–6. https://doi.org/10.1054/bjoc.1999.1035.CrossRefPubMedPubMedCentral

27.

Shi M, Yu DH, Chen Y, Zhao CY, Zhang J, Liu QH, et al. Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance. World J Gastroenterol. 2012;18:840–6. https://doi.org/10.3748/wjg.v18.i8.840.CrossRefPubMedPubMedCentral

28.

MacNeil T, Vathiotis IA, Shafi S, Aung TN, Zugazagoitia J, Gruver AM, et al. Multiplex quantitative analysis of tumor-infiltrating lymphocytes, cancer-associated fibroblasts, and CD200 in pancreatic cancer. Cancers. 2021;13. https://doi.org/10.3390/cancers13215501.

29.

Kaghazchi F, Divband G, Amini H, Adinehpour Z, Akbarian AR. 68 Ga-FAPI-46 and 18 F-FDG in advanced metastatic pancreatic cancer. Clin Nucl Med. 2022;47:e666–9. https://doi.org/10.1097/RLU.0000000000004316.CrossRefPubMed

30.

Zhang Z, Jia G, Pan G, Cao K, Yang Q, Meng H, et al. Comparison of the diagnostic efficacy of (68) Ga-FAPI-04 PET/MR and (18)F-FDG PET/CT in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022;49:2877–88. https://doi.org/10.1007/s00259-022-05729-5.CrossRefPubMed

31.

McBride WJ, Sharkey RM, Karacay H, D’Souza CA, Rossi EA, Laverman P, et al. A novel method of 18F radiolabeling for PET. J Nucl Med. 2009;50:991–8. https://doi.org/10.2967/jnumed.108.060418.CrossRefPubMed

32.

D’Souza CA, McBride WJ, Sharkey RM, Todaro LJ, Goldenberg DM. High-yielding aqueous 18F-labeling of peptides via Al18F chelation. Bioconjug Chem. 2011;22:1793–803. https://doi.org/10.1021/bc200175c.CrossRefPubMedPubMedCentral

33.

Mona CE, Benz MR, Hikmat F, Grogan TR, Lückerath K, Razmaria A, et al. Correlation of (68)Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: a prospective translational exploratory study. J Nucl Med. 2021. https://doi.org/10.2967/jnumed.121.262426.

34.

Connor AA, Gallinger S. Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data. Nat Rev Cancer. 2022;22:131–42. https://doi.org/10.1038/s41568-021-00418-1.CrossRefPubMed

35.

Wikberg ML, Edin S, Lundberg IV, Van Guelpen B, Dahlin AM, Rutegård J, et al. High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis. Tumour Biol. 2013;34:1013–20. https://doi.org/10.1007/s13277-012-0638-2.CrossRefPubMed

36.

Friemel J, Rechsteiner M, Frick L, Böhm F, Struckmann K, Egger M, et al. Intratumor heterogeneity in hepatocellular carcinoma. Clin Cancer Res. 2015;21:1951–61. https://doi.org/10.1158/1078-0432.Ccr-14-0122.CrossRefPubMed

37.

Oramas DM, Moran CA. Thymoma: challenges and pitfalls in biopsy interpretation. Adv Anat Pathol. 2021;28:291–7. https://doi.org/10.1097/pap.0000000000000310.CrossRefPubMed

38.

Mona CE, Benz MR, Hikmat F, Grogan TR, Lueckerath K, Razmaria A, et al. Correlation of (68)Ga-FAPi-46 PET Biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: interim analysis of a prospective translational exploratory study. J Nucl Med. 2022;63:1021–6. https://doi.org/10.2967/jnumed.121.262426.CrossRefPubMedPubMedCentral

39.

Troost EG, Bussink J, Slootweg PJ, Peeters WJ, Merkx MA, van der Kogel AJ, et al. Histopathologic validation of 3’-deoxy-3’-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity. J Nucl Med. 2010;51:713–9. https://doi.org/10.2967/jnumed.109.071910.CrossRefPubMed

40.

Kaps L, Schuppan D. Targeting cancer associated fibroblasts in liver fibrosis and liver cancer using nanocarriers. Cells. 2020;9. https://doi.org/10.3390/cells9092027.

41.

Klinkhammer BM, Floege J, Boor P. PDGF in organ fibrosis. Mol Aspects Med. 2018;62:44–62. https://doi.org/10.1016/j.mam.2017.11.008.CrossRefPubMed

42.

Kuburich NA, den Hollander P, Pietz JT, Mani SA. Vimentin and cytokeratin: good alone, bad together. Semin Cancer Biol. 2022;86:816–26. https://doi.org/10.1016/j.semcancer.2021.12.006.CrossRefPubMed

43.

D’Ambrosi N, Milani M, Apolloni S. S100A4 in the physiology and pathology of the central and peripheral nervous system. Cells. 2021;10. https://doi.org/10.3390/cells10040798.

44.

Li Z, Li Y, Liu S, Qin Z. Extracellular S100A4 as a key player in fibrotic diseases. J Cell Mol Med. 2020;24:5973–83. https://doi.org/10.1111/jcmm.15259.CrossRefPubMedPubMedCentral

45.

Ding J, Qiu J, Hao Z, Huang H, Liu Q, Liu W, et al. Prognostic value of preoperative [(68) Ga]Ga-FAPI-04 PET/CT in patients with resectable pancreatic ductal adenocarcinoma in correlation with immunohistological characteristics. Eur J Nucl Med Mol Imaging. 2023. https://doi.org/10.1007/s00259-022-06100-4.CrossRefPubMed

46.

Lee SM, Kim TS, Lee JW, Kim SK, Park SJ, Han SS. Improved prognostic value of standardized uptake value corrected for blood glucose level in pancreatic cancer using F-18 FDG PET. Clin Nucl Med. 2011;36:331–6. https://doi.org/10.1097/RLU.0b013e31820a9eea.CrossRefPubMed

47.

Xu HX, Chen T, Wang WQ, Wu CT, Liu C, Long J, et al. Metabolic tumour burden assessed by (1)(8)F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. Eur J Nucl Med Mol Imaging. 2014;41:1093–102. https://doi.org/10.1007/s00259-014-2688-8.CrossRefPubMed

48.

Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015;107. https://doi.org/10.1093/jnci/dju413.

49.

Kuten J, Levine C, Shamni O, Pelles S, Wolf I, Lahat G, et al. Head-to-head comparison of [(68)Ga]Ga-FAPI-04 and [(18)F]-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05494-x.CrossRefPubMedPubMedCentral

50.

Koom WS, Seong J, Kim YB, Pyun HO, Song SY. CA 19–9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;73:1148–54. https://doi.org/10.1016/j.ijrobp.2008.06.1483.CrossRefPubMed

51.

Rocha Lima CM, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, et al. Irinotecan plus gemcitabine induces both radiographic and CA 19–9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol. 2002;20:1182–91. https://doi.org/10.1200/jco.2002.20.5.1182.CrossRefPubMed

52.

Zhao L, Pang Y, Chen S, Chen J, Li Y, Yu Y, et al. Prognostic value of fibroblast activation protein expressing tumor volume calculated from [(68) Ga]Ga-FAPI PET/CT in patients with esophageal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2023;50:593–601. https://doi.org/10.1007/s00259-022-05989-1.CrossRefPubMed

53.

Fagerland MW. t-tests, non-parametric tests, and large studies–a paradox of statistical practice? BMC Med Res Methodol. 2012;12:78. https://doi.org/10.1186/1471-2288-12-78.CrossRefPubMedPubMedCentral

54.

Altman DG, Bland JM. Parametric v non-parametric methods for data analysis. BMJ (Clinical research ed). 2009;338:a3167. https://doi.org/10.1136/bmj.a3167.CrossRefPubMed

55.

Cui H, Guan J, Deng G, Yuan J, Lou C, Zhang W, et al. A Chinese retrospective multicenter study of first-line chemotherapy for advanced pancreatic cancer. Med Sci Monit. 2020;26:e927654. https://doi.org/10.12659/MSM.927654.CrossRefPubMedPubMedCentral

Titel: [18F] AlF-NOTA-FAPI-04 PET/CT can predict treatment response and survival in patients receiving chemotherapy for inoperable pancreatic ductal adenocarcinoma
verfasst von: Ziyuan Zhu
Kai Cheng
Zhang Yun
Xiang Zhang
Xiaoyu Hu
Jing Liu
Fuhao Wang
Zheng Fu
Jinbo Yue
Publikationsdatum: 17.06.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 11/2023
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-023-06271-8

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2023

Activated fibroblasts in muscle sarcoidosis revealed by [18F]FAPI-74 PET

Occipital hypometabolism is a risk factor for conversion to Parkinson’s disease in isolated REM sleep behaviour disorder

Dania Tamimi (Editor) Specialty imaging: Temporomandibular Joint and Sleep-Disordered Breathing, 2nd Edition

No impact of attenuation and scatter correction on the interpretation of dopamine transporter SPECT in patients with clinically uncertain parkinsonian syndrome

Debating the future of nuclear medicine in the light of hybrid imaging applications

Not all black colons on [18F]FDG PET are due to metformin